Earnings turned from a loss to a profit. Profit per share this year after a loss last year.
Albemarle made a profit per share in its latest year after a loss the year before.
Valuation signals disagree. Cheaper than 88% of peers on free cash flow, but only 39% on earnings.
Relative to its free cash flow, Albemarle looks cheaper than 88% of peers; relative to its earnings, cheaper than only 39%. The valuation score blends the two, so look at which measure fits this business best.
Cash flow well above reported profit. Free cash flow is 6.0× reported profit.
Free cash flow is 6.0× reported profit. Large non-cash charges, such as depreciation, amortization or stock-based pay, reduce reported profit without using cash.
More volatile share price. Beta 1.36: tends to move more than the market.
Albemarle's shares have swung more with the market than most peers' (beta 1.36, above the market's 1.0).
Since last quarter: No major changeValuation also moves with the share price every day.
Why it changed since the Oct 27, 2026 close: Score 60 → 64
Share price -8.9%+3
Peer companies moved+1
Each step re-scores the company against its peers as they were on Oct 28, 2026; the parts add up to the change. Price effects on EBITDA yield are approximate.
Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.
Questions investors ask about Albemarle
Is Albemarle getting weaker?
Its latest SEC filing (Aug 5, 2026) got stronger: turned profitable over the last 12 months; operating margin rose 7.1 points to 4.3%. Its overall score is 53/100, up 1 since Oct 28, 2026.
How is Albemarle valued vs its peers?
Priced lower than most peers relative to what it earns. Valuation scores 64/100 against 1,371 basic materials peers.Free cash flow yield 12.6% vs a peer median of 2.6% (stronger than 88% of peers).Free cash flow yield 12.6% vs peers 2.6% (stronger than 88% of peers).Earnings yield 2.1% vs a peer median of 3.6% (weaker than 61% of peers).Earnings yield 2.1% vs peers 3.6% (weaker than 61% of peers).
Is Albemarle growing?
Yes, faster than most of its peers. Growth scores 80/100 against 1,371 basic materials peers.Revenue growth 18.3% vs a peer median of 3.4% (stronger than 80% of peers).Revenue growth 18.3% vs peers 3.4% (stronger than 80% of peers).3-year revenue growth -15.1% vs a peer median of -0.0% (weaker than 91% of peers).3-year revenue growth -15.1% vs peers -0.0% (weaker than 91% of peers).
How profitable is Albemarle?
Less profitable than most of its peers. Profitability scores 31/100 against 1,371 basic materials peers.Return on invested capital 1.9% vs a peer median of 6.7% (weaker than 74% of peers).Return on invested capital 1.9% vs peers 6.7% (weaker than 74% of peers).
How risky is Albemarle?
Moderate risk relative to 1,371 basic materials peers, judged on debt, liquidity and share-price swings.Debt / equity 0.18× vs a peer median of 0.36× (stronger than 66% of peers).Debt / equity 0.18× vs peers 0.36× (stronger than 66% of peers).Beta 1.36 vs a peer median of 0.69 (weaker than 87% of peers).Beta 1.36 vs peers 0.69 (weaker than 87% of peers). A relative measure, not a bankruptcy probability.
Latest filing: what changed
Quarter ended Jun 30, 2026 · filed Aug 5, 2026 · compared with the quarter ended Mar 31, 2026
Got stronger
Turned profitable over the last 12 months
Operating margin rose 7.1 points to 4.3%
Previous quarter
Latest quarter
Change
Revenue (12 months)
5.5B USD
5.9B USD
+7.5%
Net income (12 months)
−232.9M USD
224.2M USD
turned positive
Operating margin
-2.8%
4.3%
+7.1 pts
Free cash flow (12 months)
575.5M USD
1.3B USD
+133.3%
Debt
1.9B USD
1.9B USD
−0.3%
Cash
1.1B USD
1.6B USD
+49.7%
Shares outstanding
117.9M
118.0M
+0.1%
From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.
Industry valuation context
Industry: Specialty Chemicals · 32 companies
Valuations in Specialty Chemicals are above their usual range since 2016.
74% of months since 2016 were valued lower than now.
17% of companies are in the most expensive fifth of their own price-to-sales history.
Over 24 months, company values −8% and earnings +13% (medians): earnings grew faster than prices.
Median price-to-sales is −36% vs the whole market, against a usual −31%.
2016Shaded: most expensive fifth of its range2026
This is a cyclical group: after a downturn, trailing earnings and sales fall faster than prices, which can make valuations look high near a cycle's low.
Describes valuations since 2016; it does not predict prices. US companies worth $1B+, from SEC filings and month-end prices, as of Aug 2026. Today's companies and industry labels are used throughout. Measured on earnings, EBITDA, sales and free cash flow yields. How this works
Financials
Fiscal years from SEC annual filings · change vs the prior year
Key ratios
FY 2021
FY 2022
FY 2023
FY 2024
FY 2025
Change
Gross margin
30.0%
42.0%
12.3%
1.2%
13.0%
▲ 12 pts
Operating margin
24.0%
33.7%
2.6%
-33.0%
-7.1%
▲ 26 pts
Net margin
3.7%
36.7%
16.4%
-21.9%
-9.9%
▲ 12 pts
Return on assets (ROA)
1.1%
17.4%
8.6%
-7.1%
-3.1%
▲ 4.0 pts
Return on equity (ROE)
2.2%
33.7%
16.7%
-11.8%
-5.4%
▲ 6.5 pts
Free cash flow margin
-18.3%
8.8%
-8.6%
-18.5%
13.5%
▲ 32 pts
Current ratio
1.06×
1.89×
1.47×
1.95×
2.23×
▲ 14%
Quick ratio
0.64×
1.13×
0.86×
1.19×
1.57×
▲ 32%
Debt to equity
0.43×
0.40×
0.44×
0.35×
0.33×
▼ 5.1%
ALB price history
Price history is added with the daily price update and will appear after the next one.